Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026)
Bluejay Diagnostics (BJDX) reported Cash from Financing Activities of $124096.0 for Q1 2026, up 12698.58% on a YoY basis from N/an in Q1 2025, and down 96.66% sequentially from $3.7 million in Q4 2025.
Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 6 years of Cash from Financing Activities data on file, last reported at $124096.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 12698.58% year-over-year to $124096.0; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 2.92% YoY), and the FY2025 full-year result was $7.1 million, down 30.63% from the prior year.
- Cash from Financing Activities declined to $124096.0 in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.6 million in Q2 2024 to a low of -$147861.0 in Q3 2024.
- A 4-year average of $1.4 million and a median of -$985.0 in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 283122.25% in 2024, while the deepest fall reached 112.57% in 2024.
- Tracing BJDX's Cash from Financing Activities over 4 years: stood at -$3050.0 in 2023, then jumped by 56.52% to -$1326.0 in 2024, then soared by 279980.24% to $3.7 million in 2025, then sank by 96.66% to $124096.0 in 2026.
- Business Quant data shows BJDX's Cash from Financing Activities at $124096.0 in Q1 2026, $3.7 million in Q4 2025, and -$1015.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - | 124,096.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124,096.00 |
| Mar 31, 2026 | 124,096.00 |
| Dec 31, 2025 | 3.71 Mn |
| Dec 31, 2025 | 3.71 Mn |
| Sep 30, 2025 | -1,015.00 |
| Sep 30, 2025 | -1,015.00 |
| Jun 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | -985.00 |
| Mar 31, 2025 | -985.00 |
| Dec 31, 2024 | -1,326.00 |
| Dec 31, 2024 | -1,326.00 |
| Sep 30, 2024 | -147,861.00 |
| Sep 30, 2024 | -147,861.00 |
| Jun 30, 2024 | 7.58 Mn |
| Jun 30, 2024 | 7.58 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Dec 31, 2023 | -3,050.00 |
| Dec 31, 2023 | -3,050.00 |